60 Degrees Pharmaceuticals (SXTP) said Tuesday it signed a patent license deal with Yale School of Medicine and Yale School of Public Health to jointly develop and commercialize Tafenoquine for the treatment and prevention of tick-borne disease babesiosis.
The deal comes after the start of collaboration between researchers from the organizations to look into the activity of tafenoquine against babesiosis, which is caused by microscopic parasites that infect red blood cells, the company said.
Tafenoquine currently doesn't have US Food and Drug Administration approval for babesiosis treatment and prevention, according to the company.
Shares of 60 Degrees Pharmaceuticals rose 83% in recent trading.
Price: 3.43, Change: +1.64, Percent Change: +91.68
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。